-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Sunday, Merck's Phase 3 KEYNOTE-689 Data Shows KEYTRUDA Significantly Improves Event-Free Survival As Perioperative Therapy In Locally Advanced Head And Neck Cancer

Benzinga·04/28/2025 06:41:54
Listen to the news
  • KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
  • Results to be presented at American Association for Cancer Research (AACR) Annual Meeting 2025 during a Plenary Session and included in official meeting press program